- 中文名稱
Anti-Human NRP-1
- 英文名字
- Anti-Human NRP-1
- 供應(yīng)商
- ReliaTech
- 產(chǎn)品貨號
- 102-PA23AG
- 產(chǎn)品報(bào)價(jià)
- ¥詢價(jià)/50ug

- 產(chǎn)品說明書
- 點(diǎn)擊查看
- 購買方式
- 90%產(chǎn)品中國有現(xiàn)貨庫存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金,在線支付寶及網(wǎng)銀支付,或直接與我們電話聯(lián)系400-6800-868
- 產(chǎn)品新聞

- 背景資料
- Neuropilin-1 (NRP-1, CD304) is a 130-140 kDa type I transmembrane glycoprotein that regulates axon guidance and angiogenesis. The human NRP-1 contains a 623 aa extracellular domain (ECD) that shows 92-95% aa identity with mouse, rat, bovine and canine NRP-1. The ECD contains two N-terminal CUB domains (termed a1a2), two domains with homology to coagulation factors V and VIII (b1b2) and a MAM (meprin) domain. C-terminally divergent splice variants with 704, 644, 609, and 551 aa lack the MAM and TM domains and are demonstrated or presumed to be soluble antagonists. Heparin, the heparin-binding forms of VEGF (VEGF165, VEGF-B; VEGF-E), PlGF-2, and the C-terminus of Sema3 bind the b1b2 region. NRP-1 and NRP-2 share 48% aa identity within the ECD and can form homo and hetero-oligomers via interaction of their MAM domains. Neuropilins show partially overlapping expression in neuronal and endothelial cells during development. Both neuropilins act as coreceptors with Plexins, mainly Plexin A3 and A4, to bind class III Semaphorins that mediate axon repulsion. However, only NRP-1 binds Sema3A, and only NRP-2 binds Sema 3F. Both are co-receptors with VEGFR-2 (KDR7Flk1) for VEGF165 binding. Sema 3A signaling can be blocked by VEGF165, which has higher affinity for NRP-1. NRP-1 is preferentially expressed in arteries during development or those undergoing remodeling. NRP-1 is also expressed on dendritic cells and mediates DC-induced T-cell proliferation
- 應(yīng)用類型
- WB
- 免疫原
- 該Anti-Human NRP-1的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。
- 來源宿主
- Rabbit
- 反應(yīng)性
- 該Anti-Human NRP-1的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。
- 保存建議
- 該Anti-Human NRP-1的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。
- 其他
- ReliaTech全稱為受體配體技術(shù)有限公司 (Receptor Ligand Technologies GmbH),1999年成立,總部位于德國不倫瑞克,是一家后基因組生物技術(shù)公司。ReliaTech主要專注于受體和配體的發(fā)現(xiàn)與研究。此外,ReliaTech也開發(fā)應(yīng)用于血管與淋巴管生成研究的相關(guān)高品質(zhì)試劑。目前ReliaTech提供近2800款產(chǎn)品,產(chǎn)品線主要包括重組蛋白(細(xì)胞因子、生長因子、可溶性受體)、抗體、ELISA試劑盒等。

- 注意
-
該頁面的中文產(chǎn)品信息的翻譯,僅供參考。準(zhǔn)確的產(chǎn)品信息請以廠家的英文說明書為準(zhǔn)。下單前,請瀏覽說明書確認(rèn)。
-